In a recent article in *Genome Research* [1], Thompson and colleagues present a development of a next-generation sequencing technology - the HeliScope sequencer - that enabled them to detect mutations in the human breast cancer 1 (\textit{BRCA1}) gene, as a model of a clinical diagnostic protocol. Their technique is accurate and requires limited sample preparation before sequencing. It therefore holds great promise for overcoming the emerging problem in clinical genetics of target overload: the presence of a large number of gene mutations of clinical relevance in a single disease entity. In no field is this challenge more apparent than in the genomics of cancer.

**The clinical application of next-generation sequencing**

The past few years have seen an unprecedented deluge of data on the genes mutated in cancer and other diseases. So far, the sequences of over 50 individual cancer genomes have been published and this number is set to increase exponentially. The advent of next-generation technologies (such as the Roche 454 GS FLX+, Illumina HiSeq 2000, Applied Biosystems SOLID and HeliScope single-molecule sequencer machines), which allow a human genome to be sequenced in a single week-long run, has led to a large shift in our understanding of the mutations that drive cancers [2]. For the clinician, mutations in cancer can have relevance for diagnosis, prognosis and treatment choice. However, it is now apparent that these clinically relevant mutations will be both numerous and found at low prevalence in individual cancer types. In particular, for the majority of cancers there will be no single ‘magic bullet’ targeted therapy. The breakpoint cluster region-Abelson murine leukemia homolog (BCR-ABL) fusion kinase, which is characteristic of chronic myeloid leukemia, is the exception not the rule when it comes to druggable cancer genes; it seems, instead, that multiple drug targets will be mutated at low frequency throughout common cancers [3]. This target overload is not restricted to the management of cancers and is also seen with monogenic disorders, for example, mental retardation and hereditary cancer predisposition [4].

It is therefore necessary to screen numerous genetic loci to decide on the best course of clinical management for an individual patient and this must be done in a rapid and cost-effective manner. The current technology for searching for mutations is to amplify a region of interest - in multiple fragments of a few hundred base pairs each in separate PCR reactions - then sequence the products by standard Sanger chain terminator sequencing. Although highly accurate for the detection of single-nucleotide variants and small insertions or deletions, this approach is expensive, labor intensive and unable to detect large-scale insertions or deletions. Furthermore, in tumor samples, mutations may be missed. This is because Sanger sequencing can reliably detect mutant alleles only when they are present in more than about 20% of the relevant DNA, and this will not be the case, for example, for a heterozygous mutation in a tumor contaminated with 60% normal DNA, a scenario that is not uncommon [5].

**Targeted true single-molecule sequencing**

Thompson and colleagues [1] have used a next-generation true single-molecule sequencing (tSMS) system, the HeliScope sequencer, to profile the mutational pattern of
the human cancer gene BRCA1. Germline mutations in the genes BRCA1 and BRCA2 are associated with dramatically increased rates of breast and ovarian cancers and contribute to about 10% of all breast cancer cases [6]. In addition, poly-ADP ribose polymerase inhibitors, a recently developed family of pharmaceutical agents, seem to show selective toxicity for cancers with mutations in the BRCA genes. Cost-effective sequencing of these genes is therefore a highly desirable clinical tool for the management of breast cancer patients and those with strong family histories of the disease.

The technology used is a development of the HeliScope tSMS platform [1]. In the standard HeliScope protocol, DNA is fragmented and poly(A) adaptors are added to the ends of fragments. They are then captured on a glass slide coated with covalently bound poly(dT) oligonucleotides, and sequenced [7]. Thompson et al. [1] were able to dispense with the initial sample preparation steps (addition of poly(A) adaptors and 3’ blocking - performed to prevent extension of the 3’ end of bound poly(A)-tagged DNA molecules) and instead directly captured only the fragments of DNA belonging to the BRCA1 locus, using oligonucleotides that match sequences in the BRCA1 region (Figure 1). This targeted capture approach was highly successful. Approximately 20% of the sequenced reads matched BRCA1, which equates to about 100,000-fold enrichment of the target sequence. As the length of sequence that can be read in this system is limited, oligonucleotides were designed at 20-30 base pair intervals throughout the coding sequence of the gene, to ensure complete coverage. Importantly, the authors [1] were able to obtain sequencing results from as little as 100 ng of input material - thus showing that the technology could be used with samples collected as diagnostic biopsies.

This approach [1] has several advantages over the more traditional Sanger sequencing commonly used for the detection of mutations. Firstly, there is little required in the way of sample preparation - only sonication of the DNA, and in the case of archival formalin-fixed material it is possible that even this step could be dispensed with - therefore reducing cost, turn-around time and the risk of errors in sample handling. Secondly, unlike Sanger sequencing, the HeliScope system allows the detection of large deletions, by determining the number of fragments of DNA that are present from a specific location; a decreased number of fragments from a region suggests a loss of genetic material. Finally, the HeliScope system directly sequences individual molecules rather than - as with Sanger sequencing - examining the average sequence of many millions of DNA molecules. This should provide increased sensitivity for the detection of low prevalence mutations, an essential feature in the sequencing of a heterogeneous cancer sample.

The present technology [1] is an advance over recently presented techniques for analyzing the mutational status of target genes using next-generation sequencing instruments [8,9]. With the advent of more competitively priced next-generation sequencing machines, which can provide sequence data in a matter of hours, not days (such as Life Technologies’ Ion-torrent and Illumina’s Miseq), it is feasible that such approaches could be used routinely in the clinical setting. However, the instruments involved still require the selective amplification of target DNA and the relatively complex preparation of this material for sequencing. Thus, although they take advantage of the exceptionally cheap per-base cost of next-generation sequencing, competing techniques are still limited by its flaws: high complexity and slow turnaround time. Genotyping by mass spectrometry has also been
applied to the resequencing of relevant mutations [10]. This approach, although sensitive, is limited, in that it is capable of detecting only known mutations and will therefore miss novel gene lesions.

**The future of gene sequencing in the clinic**

For the foreseeable future, the high cost and complexity of data analysis will limit the application of whole-genome sequencing for the detection of mutations in a clinical setting. Targeted resequencing of areas of interest will therefore remain key to determining mutational status. The method published by Thompson et al. [1] is a stride forward in putting this into practice. Although currently only a single gene is screened, there is clearly scope for the creation of multi-gene capture arrays, allowing large numbers of loci to be analyzed rapidly and cost-effectively with low DNA input requirements. In its simplicity, this approach provides an opportunity to truly begin integrating the vast quantity of genomic data generated in this next-generation era with clinical practice.

**Abbreviations**

BRCA, breast cancer gene; tSMS, true single-molecule sequencing.

**Competing interests**

The authors declare that they have no competing interests.

**Acknowledgements**

We would like to thank Claire Pike and Karen Howarth for helpful discussion and reading of the manuscript and the Wellcome Trust Translational Medicine and Therapeutics program, Breast Cancer Campaign and Cancer Research UK for funding.

**Published:** 12 September 2011

**References**

1. Thompson JF, Reifenberger JG, Giladi E, Kerouac K, Gill J, Hansen E, Kahvejian A, Kaplanov P, Knope T, Lipson D, Steinmann KE, Milos PM. Single-step capture and sequencing of natural DNA for detection of BRCA1 mutations. Genome Res 2011, doi: 10.1101/gr.122192.111.

2. Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ, Greenman CD, Varela I, Lin ML, Ordóñez GR, Bignell GR, Ye K, Alipaz J, Bauer MJ, Beare D, Butler A, Carter RJ, Chen L, Cox AJ, Edkins S, Kokko-Gonzales PI. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010, 463:191-196.

3. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Janne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbio H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Saliga R, Shapiro GL, Clark JW, Infrate AJ. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.

4. Vissers LE, de Ligt J, Gilissen C, Janssen I, Steenhouwer M, de Vries P, van Lier B, Arts P, Wieskamp N, del Rosario M, van Bon BW, Hoischen A, de Vries BB, Brunner HG, Velten JA. A de novo paradigm for mental retardation. Nat Genet 2010, 42:1109-1112.

5. Tiatis AC, Norris-Kirby A, Rich RG, Hafez MJ, Gocke CD, Eshleman JR, Murphy KM. Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. J Mol Diagn 2010, 12:425-432.

6. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003, 302:643-646.

7. Harris TD, Buzby PR, Babcock H, Beer E, Bowers J, Braslavsky I, Causey M, Colonell J, Dimeo J, Efcavitich JW, Giladi E, Gill J, Healy J, Jarosz M, Lapan D, Moulton K, Quake SR, Steinmann K, Thayer E, Tyuina A, Ward R, Weiss H, Xie Z. Single-molecule DNA sequencing of a viral genome. Science 2008, 320:106-109.

8. Morgan JE, Carr IM, Sheridan E, Chu CE, Hayward B, Camm N, Lindsay HA, Mattocks CJ, Markham AF, Bonthron DT, Taylor GR. Genetic diagnosis of familial breast cancer using clonal sequencing. Hum Mutat 2010, 31:484-491.

9. Walsh T, Lee MK, Casadei S, Thornton AM, Stray SM, Pennil C, Nord AS, Mandell JB, Swisher EM, King MC. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci USA 2010, 107:12629-33.

10. MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, Niu L, Davis M, Yao K, Hanna M, Mondal N, Luongo L, Emery CM, Baker AC, Phillips J, Goff DJ, Fiorentino M, Rubin MA, Poylik G, Zhan J, Wang Y, Fletcher JA, Santagata S, Corso G, Roviello F, Shidwarsin R, Kieran MW, Ligon KL, Stiles CD, Hahn WC, et al. Profiling critical cancer gene mutations in clinical tumor samples. PLoS One 2009, 4:e7887.

Cite this article as: Weaver JMJ, Edwards PAW. Targeted next-generation sequencing for routine clinical screening of mutations. Genome Medicine 2011, 3:58.